A Phase 3 interventional study of OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-30.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 11th largest by enrollment, is one of 7 that started in 2011, is one of 16 in phase 3, and was the 9th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 282 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 39th largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2011, is one of 50 in phase 3, and was the 43rd registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
To investigate the safety and efficacy of long-term administration of OPC-34712 in patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-34712
orally administered once daily
Percentage of Participants With Adverse Events
A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment.
Time frame: From Baseline up to 52 Weeks
Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS Total score ranged from 7 (best possible outcome) to 210 (worst possible outcome).
Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Mean Change From Baseline in PANSS Positive Subscale Score
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In PANSS positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Mean Change From Baseline in PANSS Negative Subscale Score
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In PANSS negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Mean Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S)
Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
Mean Clinical Global Impression - Global Improvement(CGI-I)
The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: From Baseline up to 52 Weeks including Week24, Week52, and Last Visit(LOCF)
| Milestone | New Subjects | Rollover Subjects |
|---|---|---|
| Started | 184 | 98 |
| Completed | 109 | 41 |
| Not completed | 75 | 57 |
| Withdrew: Adverse event | 19 | 22 |
| Withdrew: Protocol violation | 3 | 4 |
| Withdrew: Physician decision | 5 | 3 |
| Withdrew: Withdrawal by subject | 44 | 17 |
| Withdrew: Lack of efficacy | 4 | 11 |
A treatment-emergent adverse event (TEAE) is defined as an AE that started after start of investigational medicinal product (IMP) treatment.
| Participants | New Subjects | Rollover Subjects |
|---|---|---|
| Treatment-Emergent Adverse Events (TEAE) | 156 | 79 |
| Potentially Drug-related TEAE | 95 | 38 |
| Death | 0 | 0 |
| SAE | 19 | 18 |
| Severe Treatment-Emergent Adverse Event | 8 | 7 |
| Discontinued Due to Adverse Events | 20 | 23 |
The PANSS consisted of 3 subscales with 30 symptom constructs (positive subscale (7): delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/perseckion, and hostility; negative subscale (7): blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and conversation flow, stereotyped thinking and general psychopathology subscale (16): somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance). Severity was rated on 7-point scale with scores 1 (absence) \& 7 (extremely severe). The PANSS Total score ranged from 7 (best possible outcome) to 210 (worst possible outcome).
| units on a scale | New Subjects | Rollover Subjects |
|---|---|---|
| Week24 | -5.31 ± 9.00 | -7.20 ± 12.59 |
| Week52 | -7.01 ± 10.56 | -9.44 ± 15.16 |
| Last Visit | -3.11 ± 12.76 | -2.58 ± 15.56 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In PANSS positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| units on a scale | New Subjects | Rollover Subjects |
|---|---|---|
| WEEK24 | -1.09 ± 2.27 | -1.53 ± 3.40 |
| WEEK52 | -1.13 ± 2.73 | -1.61 ± 4.41 |
| Last Visit | -0.19 ± 3.96 | 0.24 ± 4.83 |
The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In PANSS negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| units on a scale | New Subjects | Rollover Subjects |
|---|---|---|
| Week24 | -1.64 ± 3.22 | -1.49 ± 3.84 |
| Week52 | -2.27 ± 3.85 | -2.02 ± 4.47 |
| Last Visit | -1.43 ± 3.85 | -0.89 ± 3.92 |
Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| units on a scale | New Subjects | Rollover Subjects |
|---|---|---|
| Week24 | -0.26 ± 0.71 | -0.20 ± 0.75 |
| Week52 | -0.28 ± 0.67 | -0.15 ± 0.82 |
| Last Visit | -0.13 ± 0.81 | 0.03 ± 0.92 |
The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| units on a scale | New Subjects | Rollover Subjects |
|---|---|---|
| Week24 | 3.09 ± 0.94 | 3.16 ± 0.90 |
| Week52 | 3.09 ± 0.91 | 3.22 ± 0.99 |
| Last Visit | 3.48 ± 1.22 | 3.86 ± 1.27 |
Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 30 days after the completion of the treatment period (52 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| New Subjects | 0/183 (0%) | 19/183 (10.4%) | 112/183 (61.2%) |
| Rollover Subjects | 0/98 (0%) | 18/98 (18.4%) | 50/98 (51%) |
| Event | New Subjects | Rollover Subjects |
|---|---|---|
| SchizophreniaPsychiatric disorders | 17/183 | 13/98 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/183 | 1/98 |
| Meningitis asepticInfections and infestations | 0/183 | 1/98 |
| Heat illnessInjury, poisoning and procedural complications | 0/183 | 1/98 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/183 | 1/98 |
| DehydrationMetabolism and nutrition disorders | 1/183 | 1/98 |
| AkathisiaNervous system disorders | 1/183 | 1/98 |
| Extrapyramidal disorderNervous system disorders | 1/183 | 0/98 |
| Event | New Subjects | Rollover Subjects |
|---|---|---|
| NasopharyngitisInfections and infestations | 46/183 | 19/98 |
| SchizophreniaPsychiatric disorders | 21/183 | 13/98 |
| HeadacheNervous system disorders | 19/183 | 3/98 |
| Weight increasedInvestigations | 9/183 | 10/98 |
| AkathisiaNervous system disorders | 15/183 | 7/98 |
| InsomniaPsychiatric disorders | 15/183 | 2/98 |
| TremorNervous system disorders | 4/183 | 8/98 |
| Back painMusculoskeletal and connective tissue disorders | 13/183 | 4/98 |
| SomnolenceNervous system disorders | 13/183 | 3/98 |
| EczemaSkin and subcutaneous tissue disorders | 5/183 | 6/98 |
| Age, Categorical(Participants) | New Subjects | Rollover Subjects | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 155 | 98 | 253 |
| >=65 years | 29 | 0 | 29 |
| Age, Continuous(years) | New Subjects | Rollover Subjects | Total |
|---|---|---|---|
| Mean | 45.5 ± 14.7 | 42.5 ± 12.5 | 44.4 ± 14.0 |
| Sex: Female, Male(Participants) | New Subjects | Rollover Subjects | Total |
|---|---|---|---|
| Female | 94 | 58 | 152 |
| Male | 90 | 40 | 130 |
| Region of Enrollment(participants) | New Subjects | Rollover Subjects | Total |
|---|---|---|---|
| Japan | 184 | 98 | 282 |
The record gives a start of Oct 2011 and a primary completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2019, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Co., Ltd. →